ES2494442T3 - Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico - Google Patents

Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico Download PDF

Info

Publication number
ES2494442T3
ES2494442T3 ES10721036.1T ES10721036T ES2494442T3 ES 2494442 T3 ES2494442 T3 ES 2494442T3 ES 10721036 T ES10721036 T ES 10721036T ES 2494442 T3 ES2494442 T3 ES 2494442T3
Authority
ES
Spain
Prior art keywords
isotonicity agent
adjuvant compositions
ionic
ionic isotonicity
adjuvant composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10721036.1T
Other languages
English (en)
Inventor
Veronique Henderickx
Dominique Ingrid Lemoine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2494442(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2494442T3 publication Critical patent/ES2494442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición adyuvante acuosa que comprende: (a) un agonista de TLR-4 y una saponina, en una formulación liposomal; y (b) un agente de isotonicidad no iónico, en la que la concentración de cloruro de sodio o el potencial iónico en la composición adyuvante es menor de 100 mM.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
ES10721036.1T 2009-06-10 2010-06-08 Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico Active ES2494442T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
GB0910046 2009-06-10
PCT/EP2010/058017 WO2010142685A1 (en) 2009-06-10 2010-06-08 Adjuvant compositions comprising a non-ionic isotonicity agent

Publications (1)

Publication Number Publication Date
ES2494442T3 true ES2494442T3 (es) 2014-09-15

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10721036.1T Active ES2494442T3 (es) 2009-06-10 2010-06-08 Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico

Country Status (31)

Country Link
US (2) US20120087976A1 (es)
EP (1) EP2440242B1 (es)
JP (3) JP5647677B2 (es)
KR (1) KR101473686B1 (es)
CN (2) CN104367997B (es)
AU (1) AU2010257538B2 (es)
BR (1) BRPI1012890B1 (es)
CA (1) CA2764421C (es)
CL (1) CL2011003113A1 (es)
CO (1) CO6440528A2 (es)
CY (1) CY1115522T1 (es)
DK (1) DK2440242T3 (es)
DO (1) DOP2011000346A (es)
EA (1) EA024074B1 (es)
ES (1) ES2494442T3 (es)
GB (1) GB0910046D0 (es)
HR (1) HRP20140792T1 (es)
IL (1) IL216231A0 (es)
MA (1) MA33412B1 (es)
MX (1) MX2011013162A (es)
MY (1) MY159819A (es)
NZ (1) NZ596503A (es)
PE (1) PE20120319A1 (es)
PL (1) PL2440242T3 (es)
PT (1) PT2440242E (es)
RS (1) RS53550B1 (es)
SG (1) SG176638A1 (es)
SI (1) SI2440242T1 (es)
SM (1) SMT201400134B (es)
UA (1) UA104888C2 (es)
WO (1) WO2010142685A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725140C2 (ru) 2009-06-10 2020-06-30 Чугаи Сейяку Кабусики Кайся Тетрациклические соединения
AR083246A1 (es) 2010-08-20 2013-02-13 Chugai Pharmaceutical Co Ltd Composicion que comprende compuestos tetraciclicos
ES2567190T3 (es) 2010-12-14 2016-04-20 Glaxosmithkline Biologicals S.A. Composición antigénica de micobacterias
LT2902029T (lt) 2012-09-25 2018-10-25 Chugai Seiyaku Kabushiki Kaisha Ret inhibitorius
SG10201808315UA (en) * 2014-03-25 2018-10-30 The Government Of The Us Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
PL3135287T3 (pl) 2014-04-25 2025-03-31 Chugai Seiyaku Kabushiki Kaisha Preparat zawierający związek tetracykliczny w dużej dawce
MX378186B (es) 2014-04-25 2025-03-10 Chugai Pharmaceutical Co Ltd Cristales novedosos de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo.
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途
CN107249639B (zh) 2015-01-16 2021-05-18 中外制药株式会社 联用药物
CN112812143A (zh) 2015-11-06 2021-05-18 佐剂技术公司 三萜皂苷类似物
US10695424B2 (en) * 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
CA3075822A1 (en) * 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
CN111670044A (zh) * 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
JP2021504429A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン抽出
US11939322B2 (en) 2018-09-04 2024-03-26 Chugai Seiyaku Kabushiki Kaisha Method for producing tetracyclic compound
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CN114245746A (zh) * 2019-08-05 2022-03-25 葛兰素史克生物有限公司 用于制备包含蛋白d多肽的组合物的方法
AU2024237452A1 (en) * 2023-03-15 2025-10-23 United Immunity, Co., Ltd. Lipid particle
WO2025180443A1 (en) * 2024-02-29 2025-09-04 Immunadd Inc. Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
EP0812593B8 (en) * 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
CN1306438A (zh) * 1998-05-07 2001-08-01 科里克萨有限公司 佐剂组合物及其使用方法
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1829887B1 (en) * 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Cpg single-strand deoxynucleotides for use as adjuvant
PL1896061T3 (pl) * 2005-06-27 2020-02-28 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MY153679A (en) 2007-01-15 2015-03-13 Glaxosmithkline Biolog Sa Vaccine
SI2118128T1 (sl) 2007-01-15 2013-02-28 Glaxosmithkline Biologicals S.A. Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1
TW200911304A (en) * 2007-05-24 2009-03-16 Glaxosmithkline Biolog Sa Lyophillised antigen composition
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
NZ596503A (en) 2013-08-30
CN102458457B (zh) 2015-05-20
SG176638A1 (en) 2012-01-30
CN104367997A (zh) 2015-02-25
JP6261647B2 (ja) 2018-01-17
CY1115522T1 (el) 2017-01-04
AU2010257538A1 (en) 2011-12-08
RS53550B1 (sr) 2015-02-27
JP2016193912A (ja) 2016-11-17
JP5977789B2 (ja) 2016-08-24
BRPI1012890A2 (pt) 2018-02-27
CA2764421C (en) 2016-12-06
MA33412B1 (fr) 2012-07-03
UA104888C2 (uk) 2014-03-25
EA201190286A1 (ru) 2012-06-29
EA024074B1 (ru) 2016-08-31
DK2440242T3 (da) 2014-09-01
JP2015042646A (ja) 2015-03-05
PE20120319A1 (es) 2012-04-16
EP2440242B1 (en) 2014-06-25
CL2011003113A1 (es) 2012-08-31
US20180021417A1 (en) 2018-01-25
JP5647677B2 (ja) 2015-01-07
BRPI1012890B1 (pt) 2022-03-22
KR20120031497A (ko) 2012-04-03
CO6440528A2 (es) 2012-05-15
PL2440242T3 (pl) 2014-11-28
US20120087976A1 (en) 2012-04-12
AU2010257538B2 (en) 2016-10-20
GB0910046D0 (en) 2009-07-22
MX2011013162A (es) 2012-01-30
WO2010142685A1 (en) 2010-12-16
PT2440242E (pt) 2014-08-29
IL216231A0 (en) 2012-01-31
EP2440242A1 (en) 2012-04-18
CN104367997B (zh) 2019-01-22
SI2440242T1 (sl) 2014-09-30
SMT201400134B (it) 2014-11-10
CN102458457A (zh) 2012-05-16
JP2012529464A (ja) 2012-11-22
HRP20140792T1 (hr) 2014-10-10
KR101473686B1 (ko) 2014-12-18
MY159819A (en) 2017-02-15
DOP2011000346A (es) 2012-01-15
CA2764421A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
ES2483725T3 (es) Composición básica cosmética y su uso
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
BR112022019073A2 (pt) Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
MX2019003611A (es) Formulaciones novedosas.
MX2009009463A (es) Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo.
UY33802A (es) Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
CR10101A (es) Nueva composición
PE20120326A1 (es) Formulaciones farmaceuticas para reducir la proliferacion y viabilidad de los agentes microbianos
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
CO6290622A2 (es) Composiciones de activo antitranspirante con un cromatograma sec que presenta una elevada intensidad de pico 4 sec para reducir la transpiración
PE20110162A1 (es) Yoduro de povidona, un nuevo conservante alternativo para composiciones oftalmicas
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
MX2018014631A (es) Formulacion de neurotoxina.
BR112017012978A2 (pt) composições adjuvantes aquosas contendo eletrólitos, composições contendo substância ativa e o uso das mesmas
AR108718A2 (es) Composición
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos